David A Cooper

Summary

Affiliation: University of New South Wales
Country: Australia

Publications

  1. pmc HIV research in Australia: linking basic research findings with clinical and public health outcomes
    Sharon R Lewin
    Infectious Diseases Unit, Alfred Hospital, Melbourne, Australia
    Retrovirology 3:86. 2006
  2. pmc Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa
    Richard G Wamai
    Department of African American Studies, Northeastern University, Boston, MA, USA
    J Int AIDS Soc 14:49. 2011
  3. doi Life and death in the cART era
    David A Cooper
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2052, Australia
    Lancet 372:266-7. 2008
  4. ncbi Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development
    David A Cooper
    University of New South Wales, National Centre in HIV Epidemiology and Clinical Research, St Vincent s Hospital Medical Centre, Sydney, Australia
    Lancet Infect Dis 4:426-36. 2004
  5. doi The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy
    D A Cooper
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Med 12:31-9. 2011
  6. ncbi Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    AIDS 20:1003-10. 2006
  7. doi Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    J Infect Dis 198:1794-803. 2008
  8. pmc HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy
    Allison Martin
    The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
    PLoS ONE 8:e77138. 2013
  9. ncbi Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study)
    Allison Martin
    National Centre for HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Clin Trials 5:192-200. 2004
  10. doi The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV
    Damien V Cordery
    The Kirby Institute, University of New South Wales, Sydney, Australia
    AIDS 26:2337-44. 2012

Collaborators

Detail Information

Publications139 found, 100 shown here

  1. pmc HIV research in Australia: linking basic research findings with clinical and public health outcomes
    Sharon R Lewin
    Infectious Diseases Unit, Alfred Hospital, Melbourne, Australia
    Retrovirology 3:86. 2006
    ..The meeting is expected to attract over 5000 participants and will have a dynamic and innovative programme within the three major themes of HIV basic science, clinical research and biomedical prevention...
  2. pmc Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa
    Richard G Wamai
    Department of African American Studies, Northeastern University, Boston, MA, USA
    J Int AIDS Soc 14:49. 2011
    ....
  3. doi Life and death in the cART era
    David A Cooper
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2052, Australia
    Lancet 372:266-7. 2008
  4. ncbi Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development
    David A Cooper
    University of New South Wales, National Centre in HIV Epidemiology and Clinical Research, St Vincent s Hospital Medical Centre, Sydney, Australia
    Lancet Infect Dis 4:426-36. 2004
    ..The only common adverse event associated with enfuvirtide use is injection-site reactions of generally mild-to-moderate severity, which are seldom treatment-limiting...
  5. doi The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy
    D A Cooper
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Med 12:31-9. 2011
    ..OB alone (control group) in treatment-experienced patients in the T-20 vs. Optimized Regimen Only (TORO) studies...
  6. ncbi Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    AIDS 20:1003-10. 2006
    ..To determine the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on markers of cardiovascular risk and lipodystrophy in HIV-infected, protease inhibitor (PI)-treated men with hypercholesterolaemia...
  7. doi Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    J Infect Dis 198:1794-803. 2008
    ..Rosiglitazone (RSG), a PPARgamma agonist, improves congenital lipoatrophy but not HIV lipoatrophy...
  8. pmc HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy
    Allison Martin
    The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
    PLoS ONE 8:e77138. 2013
    ....
  9. ncbi Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study)
    Allison Martin
    National Centre for HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Clin Trials 5:192-200. 2004
    ..It was hypothesized that overall improvement in LD may require a longer period of time off PIs...
  10. doi The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV
    Damien V Cordery
    The Kirby Institute, University of New South Wales, Sydney, Australia
    AIDS 26:2337-44. 2012
    ..To examine the relationship between human leukocyte antigen (HLA) genotype and body composition changes induced by thymidine analogue nucleoside reverse transcriptase inhibitor (NtRTI) use in HIV-positive individuals...
  11. doi Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards
    John M Murray
    School of Mathematics and Statistics, University of New South Wales, Sydney, New South Wales, Australia
    AIDS 26:543-50. 2012
    ..We investigated the dynamics of HIV RNA and HIV DNA levels after the commencement of raltegravir-based antiretroviral therapy (ART) in primary (PHI) and chronically HIV-infected (CHI) individuals (the PINT study)...
  12. ncbi Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study
    Allison Martin
    National Centree in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    AIDS 18:1029-36. 2004
    ..To determine if long-term improvement in HIV lipoatrophy can be attained by substitution of thymidine analogues zidovudine (ZDV) or stavudine (d4T) with abacavir (ABC)...
  13. pmc Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine
    Allison Martin
    The Kirby Institute formerly the National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
    PLoS ONE 6:e26885. 2011
    ..We examined predictors of anthropometric outcomes over 96 weeks in HIV-infected, lipoatrophic adults receiving stable cART randomised to tenofovir-emtricitabine (TDF-FTC) or abacavir-lamivudine (ABC-3TC) fixed dose combinations...
  14. doi Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection
    David A Cooper
    University of New South Wales, Sydney, Australia
    J Infect Dis 201:803-13. 2010
    ..The MERIT (Maraviroc versus Efavirenz in Treatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in antiretroviral-naive patients with R5 human immunodeficiency virus type 1 (HIV-1) infection...
  15. doi A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand
    Gail V Matthews
    Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, Sydney, NSW, Australia
    Hepatology 48:1062-9. 2008
    ..Hepatitis B e antigen (HBeAg) loss was observed in 33% of HBeAg-positive subjects, and 8% experienced hepatitis B surface antigen loss. Hepatic flare was observed in 25% of subjects...
  16. pmc Progressive activation of CD127+132- recent thymic emigrants into terminally differentiated CD127-132+ T-cells in HIV-1 infection
    Sarah C Sasson
    The Kirby Institute, The University of New South Wales, Sydney, Australia
    PLoS ONE 7:e31148. 2012
    ..We investigated the correlates of loss of CD127 from the T-cell surface to understand mechanisms underlying this homeostatic dysregulation...
  17. ncbi Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
    John M Murray
    National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW 2052, Australia
    AIDS 21:2315-21. 2007
    ..To date, there have been no reports investigating the potential for differential effects on viral dynamics with integrase inhibitors relative to current antiretroviral drugs...
  18. ncbi Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort
    W Phillip Law
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Darlinghurst, Sydney, Australia
    AIDS 18:1169-77. 2004
    ..To examine the impact of viral hepatitis co-infection on HIV disease outcomes following commencement of combination antiretroviral therapy in a developing country setting...
  19. doi Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial
    Allison Martin
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    AIDS 24:2657-63. 2010
    ..7, P = 0.048) in ABC/3TC recipients compared with TDF/FTC in the STEAL study. The impact of ABC/3TC treatment on a range of CVD and inflammatory biomarkers was explored...
  20. ncbi A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients
    Sarah L Pett
    HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 14:111-5. 2009
    ..SCH532706 is a novel small molecule chemokine receptor-5 (CCRS) antagonist with high in vitro potency (mean 90% inhibitory concentration [IC90] 0.15-7.0 nM) against diverse HIV type-1 (HIV-1) isolates...
  21. ncbi The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Clin Infect Dis 44:1475-83. 2007
    ..Ritonavir-boosted double-protease inhibitor (PI)-only regimens are such an option but are prone to pharmacokinetic interactions...
  22. doi Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial
    Allison Martin
    National Centre in HIV Epidemiology and Clinical Research UNSW, 5St Vincent s Centre for Applied Medical Research, Sydney, Australia
    Clin Infect Dis 49:1591-601. 2009
    ..Which fixed-dose-combination tablet is more effective and safe is uncertain...
  23. pmc HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy
    John M Murray
    School of Mathematics and Statistics, University of New South Wales, Sydney, NSW, Australia
    J Virol 88:3516-26. 2014
    ..These results provide insights into the interrelatedness of cell activation and reservoir maintenance, with implications for the design of therapeutic strategies targeting HIV persistence...
  24. pmc Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
    Allison Martin
    aThe Kirby Institute, University of New South Wales, Sydney, Australia bUCD School of Medicine and Medical Science, Dublin, Ireland cThe Alfred Hospital, Melbourne, Australia dCICAL, Buenos Aires, Argentina eThai Red Cross AIDS Research Center, Bangkok, Thailand fHopital Saint Louis, Paris, France
    AIDS 27:2403-11. 2013
    ....
  25. ncbi Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individuals
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, NSW 2010, Australia
    AIDS Res Hum Retroviruses 22:338-41. 2006
    ..In this cohort of highly treatment-experienced individuals treated with NNRTI regimens, we did not observe a significant association between NNRTI plasma concentration and virological response...
  26. ncbi Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy
    Jason C Kovacic
    Cardiology Department, HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 10:135-43. 2005
    ..This study sought to investigate the effects of rosiglitazone on endothelial function and other markers of cardiovascular risk in patients with HIV-related lipoatrophy...
  27. ncbi Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy
    Gail V Matthews
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    AIDS 20:863-70. 2006
    ..Little is known about the prevalence and pattern of hepatitis B virus (HBV) mutations in HIV/HBV co-infected individuals on long-term lamivudine (3TC) therapy...
  28. ncbi Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, 2010, Australia
    J Antimicrob Chemother 56:380-7. 2005
    ..The aim of this study was to assess the clinical associations with plasma atazanavir concentrations in HIV-positive individuals...
  29. ncbi Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection
    Handan Wand
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    AIDS 21:2445-53. 2007
    ..Metabolic syndrome (MS) identifies individuals at risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Little is known about MS and its consequences following initiation of antiretroviral therapy (ART)...
  30. doi Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
    David A Cooper
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney
    N Engl J Med 359:355-65. 2008
    ....
  31. ncbi Rates of transmission of antiretroviral drug resistant strains of HIV-1
    Palanee Ammaranond
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney 2010, NSW, Australia
    J Clin Virol 26:153-61. 2003
    ....
  32. doi A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection
    Sarah L Pett
    HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    AIDS Res Hum Retroviruses 26:653-61. 2010
    ..The persistence and clinical meaning of these immunological changes during long-term exposure to this class of anti-HIV drugs are unknown, but may have implications for immunosurveillance of inflammation...
  33. doi Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression
    Helen Byakwaga
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, NSW 2010, Australia
    AIDS Res Hum Retroviruses 25:756-76. 2009
    ..Our results point to an advantage to commencing ART at higher CD4+ T cell strata. These data should be considered when estimating the optimal time to initiate ART...
  34. doi A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults
    Dianne Carey
    Kirby Institute University of New South Wales, Sydney, Australia
    J Acquir Immune Defic Syndr 60:143-9. 2012
    ..New antiretroviral drug classes provide opportunities to explore novel regimens...
  35. doi Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir
    Kersten K Koelsch
    The Kirby Institute, University of New South Wales, Sydney, Australia
    AIDS 25:2069-78. 2011
    ..In most patients, rebound upon treatment cessation is prompt. We assessed whether early treatment with raltegravir can impact on the formation of the viral reservoir...
  36. doi A culture amplified multi-parametric intracellular cytokine assay (CAMP-ICC) for enhanced detection of antigen specific T-cell responses
    C Mee Ling Munier
    HIV Immunovirology Laboratory, St Vincent s Centre for Applied Medical Research, Sydney, NSW, Australia
    J Immunol Methods 345:1-16. 2009
    ..The CAMP-ICC provides much more information than conventional functional T-cell assays allowing simultaneous determination of proliferative capacity and cytokine production by both CD4 and CD8+ T cells...
  37. doi Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial
    Helen Byakwaga
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    J Infect Dis 204:1532-40. 2011
    ..This study aimed to determine the effect of intensification of cART with raltegravir or addition of hyperimmune bovine colostrum (HIBC) on CD4(+) T-cell count in such patients...
  38. doi Persistent survival of prevalent clonotypes within an immunodominant HIV gag-specific CD8+ T cell response
    David J van Bockel
    St Vincent s Centre for Applied Medical Research, University of New South Wales, Sydney, New South Wales, Australia
    J Immunol 186:359-71. 2011
    ....
  39. doi Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study
    Rebekah L Puls
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, 45 Beach St, Coogee, New South Wales, Australia, 2034
    Clin Infect Dis 51:855-64. 2010
    ..Antiretroviral therapy is complicated by drug interactions and contraindications. Novel regimens are needed...
  40. doi Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study
    Alexandra Calmy
    HIV, Immunology and Infectious Diseases Unit, University of New South Wales, Sydney, Australia
    J Infect Dis 200:1746-54. 2009
    ..The role of proximal renal tubular dysfunction (PRTD) and alterations in bone metabolism in HIV-related low BMD are incompletely understood...
  41. doi Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients
    Damien V Cordery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Antivir Ther 15:1035-8. 2010
    ....
  42. doi Human antigen-specific CD4⁺ CD25⁺ CD134⁺ CD39⁺ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses
    Nabila Seddiki
    The Kirby Institute, University of New South Wales, Sydney, NSW, Australia St Vincent s Centre for Applied Medical Research, Sydney, NSW, Australia
    Eur J Immunol 44:1644-61. 2014
    ..Identification and isolation of these cells enables the role of Treg cells in memory responses to be further defined and provides a development pathway for novel therapeutics. ..
  43. pmc Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency
    Denise C Hsu
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    PLoS ONE 8:e77479. 2013
    ..This study characterized the dynamics of CMV-Sp-CD4 after ART initiation and explored associations with CD4 T cell recovery as well as frequency of naïve CD4 T cells at week 96...
  44. ncbi The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals
    Alan Winston
    National Centre for HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
    AIDS 19:1393-9. 2005
    ..We undertook an assessment of NIQ and 48-week virological outcome in patients commencing ritonavir-boosted protease inhibitor (PI) regimens...
  45. ncbi Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir
    Gail V Matthews
    HIV Immunology Infectious Diseases Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 12:119-22. 2007
    ..The safety and efficacy of tenofovir in HIV/HBV cirrhosis has not been previously described...
  46. ncbi No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial
    Andrew Carr
    St Vincent s Hospital, Sydney, Australia
    Lancet 363:429-38. 2004
    ..We postulated that rosiglitazone would improve HIV lipoatrophy...
  47. pmc The majority of HIV type 1 DNA in circulating CD4+ T lymphocytes is present in non-gut-homing resting memory CD4+ T cells
    Kristin McBride
    1 The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    AIDS Res Hum Retroviruses 29:1330-9. 2013
    ..Our investigations showed that the majority of both total and integrated HIV-1 DNA was found within non-gut-homing resting CD4(+) T cells...
  48. ncbi Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals
    Amit C Achhra
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    AIDS 26:1707-17. 2012
    ..To evaluate the change in categories of risk of death by adding D-dimer to conventional mortality risk factors...
  49. pmc Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia
    Alexander Hoare
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    PLoS ONE 5:e10981. 2010
    ..Universal access to first-line antiretroviral therapy (ART) for HIV infection is becoming more of a reality in most low and middle income countries in Asia. However, second-line therapies are relatively scarce...
  50. doi IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers
    Sarah C Sasson
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Cytokine 50:58-68. 2010
    ..Patients with B-cell derived neoplasms had elevated circulating IL-10 and decreased BAFF. These findings support a role for the IL-7/IL-7R system in B-cell oncogenesis...
  51. ncbi Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, Sydney, Australia
    J Acquir Immune Defic Syndr 38:156-62. 2005
    ....
  52. ncbi Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy
    Seng Khee Gan
    Metabolism and Diabetes Research Program, Garvan Institute of Medical Research, Sydney, Australia
    Diabetes 51:3163-9. 2002
    ..The results do not establish causation but emphasize the interrelationships among visceral fat, myocyte lipid, and insulin action...
  53. doi Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy
    Hila Haskelberg
    The Kirby Institute, University of New South Wales, Sydney, Australia UCD School of Medicine and Medical Science, Dublin, Ireland The Alfred Hospital, Melbourne, Australia Thai Red Cross AIDS Research Center, Bangkok, Thailand Hopital Saint Louis, Paris, France and CICAL, Buenos Aires, Argentina
    J Acquir Immune Defic Syndr 67:161-8. 2014
    ....
  54. doi Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapy
    Denise C Hsu
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand Electronic address
    J Infect 68:344-54. 2014
    ..Despite antiretroviral therapy (ART), HIV-infected persons have increased risk of active tuberculosis (TB). PPD and combined ESAT-6 and CFP-10-specific-CD4 (EC-Sp-CD4) responses were examined over 96 weeks...
  55. pmc Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting
    John M Murray
    1 School of Mathematics and Statistics, University of New South Wales, Sydney, NSW, Australia
    AIDS Res Hum Retroviruses 29:1621-5. 2013
    ..The high Amplicor assay error rate around this level implies that viral blips underrepresent pVL being more consistently above the LLOQ. Activation of latently infected cells is less likely to contribute to this phenomenon...
  56. ncbi The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse)
    Mark T Bloch
    Holdsworth House Medical Practice, Sydney, New South Wales, Australia
    J Acquir Immune Defic Syndr 42:192-202. 2006
    ..The addition of hydroxyurea (HU) may reduce viral production from activated CD4 cells...
  57. pmc Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA
    Yu Ming Paul Lam
    The Kirby Institute, University of New South Wales, Sydney, Australia
    PLoS ONE 7:e31990. 2012
    ....
  58. doi A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assays
    Denise C Hsu
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, NSW, Australia
    Tuberculosis (Edinb) 92:321-7. 2012
    ..Further study into the performance of this assay is thus warranted...
  59. ncbi A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy
    Dianne L Carey
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    J Acquir Immune Defic Syndr 46:581-9. 2007
    ..Facial lipoatrophy can stigmatize and can reduce quality of life, self esteem, and antiretroviral adherence. Poly-L-lactic acid (PLA) injections seem safe and effective, but no randomized study has included objective endpoints...
  60. ncbi Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy
    Don E Smith
    National Centre for HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Clin Trials 4:45-9. 2003
    ..The aim of this study was to investigate the variability of dual-energy X-ray absorptiometry (DEXA) scans analysis performed at local sites compared to central analysis in a multicenter clinical trial...
  61. ncbi Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion
    Don E Smith
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
    AIDS Res Hum Retroviruses 19:189-99. 2003
    ..Despite poorer prognostic markers at baseline ES subjects achieved responses similar to those of LS subjects after 1 year of treatment...
  62. ncbi Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial
    Dianne Carey
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    AIDS 19:1325-7. 2005
    ..Changes in facial fat assessed by ultrasonography did not correlate significantly with more established objective measures of lipoatrophy severity. The measurement of malar fat using ultrasonography is not recommended...
  63. pmc Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression
    Kathleen Falster
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    J Acquir Immune Defic Syndr 50:307-13. 2009
    ..To determine the prevalence and predictors of an incomplete immune response in patients with sustained viral suppression after starting their first or second combination antiretroviral treatment (cART) regimen...
  64. doi Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels
    William J Hey-Cunningham
    aThe Kirby Institute, UNSW Australia, Sydney bCentre for Applied Medical Research, St Vincent s Hospital Sydney, Sydney cSchool of Mathematics and Statistics, UNSW Australia, Sydney, Australia dLeidos Biomedical Research Inc, Frederick, Maryland, USA eSt Vincent s Hospital Sydney, Sydney, Australia Dr Anthony D Kelleher and Dr Kersten K Koelsch contributed equally to the writing of this article
    AIDS 29:911-9. 2015
    ..Current evidence for the advantages of early ART, however, are mostly derived from cross-sectional studies, with the long-term benefits yet to be ascertained...
  65. doi Changes in metabolic, inflammatory and coagulation biomarkers after HIV seroconversion--the Health in Men (HIM) Biomarker Substudy
    Amit C Achhra
    Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    Antivir Ther 18:355-9. 2013
    ..Biomarkers of inflammation, coagulation, lipids and vitamin D have been associated with cardiovascular and mortality risk in HIV-infected individuals. Scarce data exist on changes in these markers from pre- to post-HIV seroconversion...
  66. pmc Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques
    Yin Xu
    Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia
    J Virol 87:3760-73. 2013
    ..Infection of Tfh cells does not interrupt antibody production but may be a factor that limits the quality of antibody responses and has implications for assessing the size of the viral reservoir...
  67. pmc The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa
    Karen Schneider
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, New South Wales, Australia
    PLoS ONE 8:e54435. 2013
    ....
  68. doi Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up
    D Carey
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW, Australia
    HIV Med 10:163-72. 2009
    ..Poly-l-lactic acid (PLA) injections modestly increase objectively assessed facial thickness but not facial soft tissue volume (FSTV) over 24 weeks. The durability of this response has not been well defined objectively...
  69. pmc CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts
    Stephen T Wright
    The Kirby Institute formally National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, New South Wales 2010, Australia
    J Acquir Immune Defic Syndr 58:72-9. 2011
    ..To examine CD4 cell responses to combination antiretroviral therapy (cART) in patients enrolled in the Australian HIV Observational Database who commenced cART at CD4 cell counts >350 cells per microliter...
  70. pmc Validation of RNA-based molecular clonotype analysis for virus-specific CD8+ T-cells in formaldehyde-fixed specimens isolated from peripheral blood
    David van Bockel
    Centre for Immunology, St Vincent s Hospital, Sydney, NSW, Australia
    J Immunol Methods 326:127-38. 2007
    ....
  71. ncbi Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults
    Matthew Law
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Antivir Ther 11:179-86. 2006
    ..To compare three versions of the objective HIV-associated lipodystrophy (HIVLD) case definition (LDCD) and derived severity scale to spontaneous clinical LD assessment in adults initiating antiretroviral therapy...
  72. ncbi Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy
    Patrick W Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    AIDS 17:971-9. 2003
    ..To investigate this a study was designed to explore changes in body composition occurring with antiretroviral therapy...
  73. ncbi Methodological considerations in human studies of gene expression in HIV-associated lipodystrophy
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Antivir Ther 10:M101-8. 2005
    ..Careful collection and processing of adequate biological samples, robust laboratory processes and assays, and appropriate study design can help overcome many of these difficulties...
  74. pmc Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand
    Anchalee Avihingsanon
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    AIDS Res Ther 9:6. 2012
    ..Hepatic Flare (HF) after initiation of highly active antiretroviral therapy (HAART) in HIV-HBV coinfected individuals is well recognized but prospective data on predictors and subsequent outcome are limited...
  75. pmc Trends in detectable viral load by calendar year in the Australian HIV observational database
    Matthew G Law
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
    J Int AIDS Soc 14:10. 2011
    ..We assessed calendar trends in detectable viral load in patients recruited to the Australian HIV Observational Database who were receiving cART...
  76. doi Optimal antiretroviral therapy for aging
    Damien V Cordery
    The Kirby Institute, University of New South Wales, Sydney, NSW 2010, Australia
    Sex Health 8:534-40. 2011
    ..The increase in HIV prevalence in older age groups has not been accompanied by the development of treatment guidelines or recommendations for appropriate antiretroviral therapy or clinical management in these patients...
  77. ncbi Increased plasma interleukin-7 level correlates with decreased CD127 and Increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infection
    Sarah C Sasson
    National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia
    J Infect Dis 193:505-14. 2006
    ....
  78. ncbi Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection
    Gregory J Dore
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    AIDS 21:1555-9. 2007
    ..To identify baseline characteristics predictive of a sustained virological response (SVR) in patients with HIV-hepatitis C virus (HCV) co-infection treated with interferon-based therapy...
  79. ncbi A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1
    Palanee Ammaranond
    National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW, Australia
    AIDS Res Hum Retroviruses 21:395-7. 2005
    ..A peptide binding assay confirmed that the R264Q mutant peptide had 30-fold lower binding affinity to HLA-B27 compared to wild type. Therefore, the R264Q variant is a likely novel escape mutation in HLA-B27-positive individuals...
  80. pmc Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients
    Amit C Achhra
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, Cliffbrook Campus, Coogee, Sydney, New South Wales, Australia
    AIDS 24:1877-86. 2010
    ..To investigate the relative predictive value of CD4(+) metrics for serious clinical endpoints...
  81. doi Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings
    Karen Schneider
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    AIDS 25:1143-51. 2011
    ..We investigated the cost-effectiveness and cost-utility of different frequencies of monitoring plasma viral load among HIV-positive children initiating ART in a resource-limited setting...
  82. doi High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40)
    John J Zaunders
    Centre for Immunology, St Vincent s Hospital, Sydney, New South Wales, Australia
    J Immunol 183:2827-36. 2009
    ..In addition to revealing the true extent of Ag-specific human CD4(+) memory T lymphocytes, its greatest use will be as a simple in vitro monitor of CD4(+) T cell responses to Ags such as tuberculosis infection or vaccines...
  83. doi Relation between HIV viral load and infectiousness: a model-based analysis
    David P Wilson
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
    Lancet 372:314-20. 2008
    ..We analysed the implications of this statement at a population level...
  84. ncbi Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research
    Mark A Boyd
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
    AIDS 21:S55-63. 2007
    ..Therefore, the funding bodies responsible for the roll-out of antiretroviral access across the globe must mandate, incorporate and fund clinical research as an intrinsic aspect of combination ART roll-out programmes...
  85. ncbi In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, NSW 2010, Australia
    J Infect Dis 191:1686-96. 2005
    ..The effects of this mitochondrial dysfunction on lipid metabolism, at a molecular level in vivo, have not been described...
  86. ncbi Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001
    W Phillip Law
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    AIDS 17:2191-9. 2003
    ..To examine rates and predictors of severe hepatotoxicity with combination antiretroviral therapy in a developing country setting: the eight HIV-NAT randomized controlled trials in Thailand...
  87. pmc Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals
    John M Murray
    School of Mathematics and Statistics, University of New South Wales, Sydney 2052, NSW, Australia
    J Virol 85:10798-805. 2011
    ..The mean estimated half-life of plasma virions was 5 min, significantly shorter than previous estimates...
  88. ncbi No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001
    Palanee Ammaranond
    National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW, Australia
    AIDS 17:264-7. 2003
    ..Primary resistance mutations in the protease gene are still rare...
  89. doi Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy
    Julian H Elliott
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    J Infect Dis 200:1736-45. 2009
    ..In many settings, the benefits of antiretroviral therapy (ART) are reduced by the high early incidence of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS)...
  90. ncbi The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy
    Gilbert R Kaufmann
    National Centre in HIV Epidemiology and Clinical Research, Sydney NSW, 2010, Australia
    AIDS 16:359-67. 2002
    ..To study the long-term immunological recovery in HIV-1-infected individuals receiving potent antiretroviral therapy (ART)...
  91. pmc Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples
    Wayne B Dyer
    Australian Red Cross Blood Service, 153 Clarence Street, Sydney, NSW 2000, Australia
    Clin Vaccine Immunol 14:52-9. 2007
    ....
  92. ncbi Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study
    Don E Smith
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    AIDS 16:2489-91. 2002
  93. doi Clinical research in NSW: its role in HIV care and prevention
    Damien V Cordery
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales
    N S W Public Health Bull 21:93-5. 2010
    ..National and international collaboration are essential in identifying and managing the complex factors required for the current management of HIV and the potential mechanisms for the future elimination of HIV...
  94. ncbi Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus
    Gregory J Dore
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    J Infect Dis 189:1185-92. 2004
    ..Lamivudine has potent activity against both HIV-1 and HBV; however, lamivudine-resistance mutations in HBV frequently develop...
  95. ncbi HIV medicine
    Sean Emery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010
    Med J Aust 176:21. 2002
  96. ncbi Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression
    Elizabeth Keoshkerian
    Department of Immunology and Infectious Diseases, Sydney Children s Hospital, Randwick, Australia
    J Med Virol 71:483-91. 2003
    ..These findings demonstrate the importance of HIV replication in generating an effector CTL response and show that effector CTL activity may be an early predictor of progression in people with long-term asymptomatic HIV infection...
  97. ncbi The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT
    Sean Emery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Sydney, NSW 2010, Australia
    Control Clin Trials 23:198-220. 2002
    ..This article describes the rationale supporting the trial in addition to reviewing the study design, coordination, and governance...
  98. ncbi HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, St Vincent s Hospital Medical Centre, 376 Victoria Street, Sydney NSW 2010, Australia
    Curr Diab Rep 2:116-24. 2002
    ..Treatment strategies, normally successful in the general population, have generally been less effective in this group of people, in which the detrimental effects of the antiretroviral medications are ongoing...
  99. pmc The TREAT Asia HIV Observational Database: baseline and retrospective data
    Jialun Zhou
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    J Acquir Immune Defic Syndr 38:174-9. 2005
    ....
  100. ncbi Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, St Vincent s Hospital Medical Centre, University of New South Wales, 376 Victoria Street, Sydney NSW 2010, Australia
    J Clin Virol 26:223-7. 2003
    ..Nevertheless, it has a potentially important role to play in the management of HIV-infected patients, with the aim of limiting toxicity, optimising antiviral effect and decreasing virological failure and emergence of viral resistance...
  101. ncbi Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection
    John J Zaunders
    Centre for Immunology, St Vincent s Hospital, Victoria St, Darlinghurst, NSW 2010 Australia
    Blood 106:1660-7. 2005
    ..These results suggest that the antiviral response to HIV-1 infection includes highly activated CCR5(+)CD4(+) cytotoxic effector cells, which are susceptible to both apoptosis and cytopathic infection with HIV-1, and rapidly decline...